Research Funded

MPN Research Foundation Grant Recipients

Since 2000, the MPN Research Foundation (formerly MPD Foundation) has awarded grants to worthy MPN researchers on a quest to advance the science of MPNs in the field of drug development, epidemiology and general research. To date, the Foundation has awarded over $10 million for MPN research, including these grants. Click here for types of research we fund and how to apply for a grant.


New funding (Two year grants for $100,000 each year, with second year funding contingent on progress):

Angela G. Fleischman, M.D., PhD, University of California, Irvine
Project Title:  Inflammation as a Driver of Clonal Expansion in Myeloproliferative Neoplasm

James D. Griffin, M.D., Martin Sattler, Ph.D., Sara J. Buhrlage Ph.D., Ellen L. Weisberg Ph.D., Dana Farber Cancer Institute
Project Title:  Inhibition of deubiquitinating enzymes as a novel targeted therapy for JAK2-dependent myeloid malignancies

Vivian G. Oehler, M.D., Marie Bleakley, M.D., Ph.D., Fred Hutchinson Cancer Research Center  
Project Title:  Characterizing myeloproliferative neoplasm neoantigens and T cell responses for therapeutic applications 

Stephen Oh, M.D., Ph.D., Washington University in St. Louis
Project Title:  Leveraging NFKB Pathway Dysregulation for Therapeutic Benefit in Myeloproliferative Neoplasms

Rebekka K. Schneider, M.D. & Rafael Kramann, M.D., Department of Hematology, Erasmus University Medical Center, Cancer Institute, Rotterdam, The Netherlands & Department of Nephrology, RWTH Aachen University, Aachen, Germany
Project Title:  Functional and molecular dissection of the fibrotic transformation and clonal selection in myeloproliferative neoplasms

2015 - 2017

New funding (Two year grants for $100,000 each year, with second year funding contingent on progress):

George Church, PhD Click here for project details
Harvard Medical School
"Establishment of isogenic human induced pluripotent stem cell (hiPSC) lines containing CRISPR engineered MPN mutations"

Camelia Iancu-Rubin, PhD and Nina Bhardwaj, MD, PhD Click here for project details
Icahn School of Medicine at Mount Sinai
"Defining the immunomodulatory properties of mutated calreticulin in MPN"

Zhijian Qian, PhD and Wen-Shu Wu, PhD Click here for project details
University of Illinois at Chicago
"Correction of JAK2 mutation in myeloproliferative neoplasms by gene editing"

Brady Stein, MD Click here for project details
Northwestern Feinberg School of Medicine
"Anti-PDL1 therapy for patients with Myelofibrosis"

Zhaohui Ye, PhD Click here for project details
Johns Hopkins
"Precise Genome Editing for Targeting Malignant Clones in MPNs"

Continued funding (project descriptions are below for 2014-2015):

Nadia Carlesso, MD, PhD
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine 

Robert Kralovics, PhD
Center for Molecular Medicine of the Austrian Academy of Sciences - Read more.

Katya Ravid, MD, PhD
Boston University School of Medicine

Leonard Zon, MD
Boston Children's Hospital

2014 - 2015

Steven Hubbard, PhD
New York University
"Testing for small molecules for selective JAK2 inhibition"

MPN Challenge

Nadia Carlesso & H. Schott Boswell 
Indiana University School of Medicine
“Impact of the inflamed bone marrow niche on the progression of Myeloproliferative Neoplasia and marrow fibrosis” - Read More

Michael Deininger
Huntsman Cancer Institute, University of Utah School of Medicine
“Engineering CAR T Cells That Target Mutant CALR as a Novel Therapeutic for Myeloproliferative Neoplasms”

Angela Fleischman & Richard Van Etten
University of California, Irvine
“A key role for lymphoid cells in the pathology of myeloproliferative neoplasm”

Lei Ding
Columbia University Medical Center
“Hematopoietic stem cell niche in myelofibrosis”

Robert Kralovics
CEMM, Austria
“Immunologic Targeting of Calreticulin Gene Mutations in MPN”

Ann Mullally
The Brigham and Women’s Hospital
“Determination of the role of altered epigenetic regulation of megakaryocytes in the pathogenesis of myelofibrosis”

Katya Ravid
Boston University School of Medicine
“Nanoplatforms for Imaging Bone Marrow Fibrosis”

Gary W. Reuther
Moffitt Cancer Center
“Using Pharmacological Synthetic Lethality to Treat MPNs”

Jean-Luc Villeval, Sandra Pellegrini, Stefan Constantinescu
INSERM/Institut Gustave Roussy/University Paris XI, France; Institut Pasteur Paris, France; de Duve Institute, Université catholique de Louvain, Brussels, Belgium and Ludwig Cancer Research Institute, Brussels, Belgium
“Project Title: Mechanisms of Sensibility and Resistance of MPN Hematopoietic Stem Cells to IFNα Therapy”

Leonard Zon
Boston Children’s Hospital
“Identifying factors that promote clonal dominance in zebrafish hematopoiesis for the treatment of myeloproliferative neoplasms”

2013 - 2014

MF Challenge

John Varga and Jonathan Licht
Northwestern University
"Adipocytes - the cell of origin of fibrosis in myeloproliferative neoplasm?"

Golam Mohi
State University of New York
"Molecular mechanism of myelofibrosis induced by JAK2V617F"

Emmanuelle Passegué
University of California at San Francisco
"Targeting the remodeling of the osteoblastic bone marrow niche by MPN myeloid cells to prevent myelofibrosis"

Xiaoli Wang
Mt. Sinai School of Medicine
"The role of thrombopoietin and its receptor in myelofibrosis"

2011 - 2013

MF Challenge

Ann Mullaly & Benjamin L. Ebert
Brigham and Women's Hospital
"Determination of the cytokines that are necessary and sufficient to include fibrotic transformation in JAK2V617F-mediated MPN"

Amit Verma and Zhizhuang Joe Zhao
Albert Einstein College of Medicine & University of Health Sciences Center
"Efficacy of a clinically relevant TGF-Beta receptor kinase inhibitor in myelfibrosis"

Pearlie Epling-Burnette and Adam Mailloux
H. Lee Moffitt Cancer Center
"Blockade in mesenchymal stromal self-renewal as a novel mediator of the profibrotic marrow phenotype"

C. Arnold Spek
Center for Experimental and Molecular Medcine, Austria
"Bone marrow fibrosis: proof of principle for a potential therapeutic role of protease activated receptor inhibitors"

Established Investigators:

Ruben Mesa, MD
Mayo Clinic, Scottsdale
"Validation of use of the Myeloproliferative Neoplasm Symptom Assessment Form Diary to Assess Symptomatic Pains in Patients with Polycythemia Vera and Post Polycythemia Vera"

Established Investigators:

Robert I. Handin, MD
Brigham and Women's Hospital, Harvard Medical School
"HDAC Inhibitors and Red Cell Proliferation in Zebrafish Embryos Expressing Human JAK2V617F"

Shaoguang Li, MD PhD
University of Massachusetts Medical School
"Identification of Alox5 as a Potential Target Gene for the Treatment of Polycythemia Vera"

Robert Kralovics, PhD
Austrian Academy of Sciences, Vienna
"Deciphering the Genetic Complexity of Myeloproliferative Disorders"
Research results: Discovery of CALR genetic mutation for MPNs (December 2013)

Benjamin Ebert, MD PhD and Ross Levine, MD
Harvard Medical School and Memorial Sloan Kettering, respectively
"Whole Genome Sequencing to Identify Germline and Somatic Disease Alleles Which Contribute to MPD Pathogenesis"

New Investigators:

Toshiaki Kawakami, MD PhD
La Jolla Institute for Allergy and Immunology
"SPS Complex in MPD"

Wei Tong, PhD
Children's Hospital of Pennsylvania
"K63 Ubiquitination in JAK2 Signaling and Myeloproliferative Neoplasms"

Saghi Ghaffari, MD PhD
Mt. Sinai School of Medicine
"Understanding Molecular Mechanisms of Regulation of Myeloproliferative Disorders in Mouse and Human"


MPD Research Alliance:

Gary Gilliland, MD, PhD
Harvard Medical School
"Genetics and Therapy of Myeloproliferative Disorders"

Ronald Hoffman, MD
Mt. Sinai School of Medicine
"Use of Stem Cells Derived from the Philadelphia Chromosome Negative Myeloproliferative Disorders as a Chemotherapeutic Target"

Josef Prchal, MD
University of Utah
Define somatic mutations that precede JAK2 mutation in PV patients & monitor their changes in response to Pegasys"

Ayalew Tefferi, MD
Mayo Clinic
"Continued Development of Clinical Database-Linked Cell and Serum Bank of Patients with Myeloproliferative Disorders"

New Investigator:

Benjamin Braun, MD, PhD
University of California, San Francisco
"Oncogenic Ras in Leukemia Stem Cells"

Francois Delhommeau, PhD, PharmD
Saint-Antoine Hospital, Paris
"Characterization and Function of a New Tumor Suppressor Gene in Myeloproliferative Disorders"

Robert Kralovics, PhD
Austrian Academy of Sciences, Vienna
"Genomic approaches for disease gene identification in myeloproliferative neoplasms"

Dorothy Sipkins, MD, PhD
University of Chicago
"In Vivo Imaging of PV and CIMF CD34+ Progenitor Cell Interactions with Bone Marrow Microenvironment"


Gary Gilliland, PhD, MD (MPD Research Alliance)
Harvard Medical School

Ayalew Tefferi, MD (MPD Research Alliance)
Mayo Clinic, Rochester

Ronald Hoffman, PhD (MPD Research Alliance)
Mt. Sinai School of Medicine (2007-Present)
University of Illinois, Chicago (2006-2007)

Gail Roboz, MD
Weill Cornell Medical College
"Arsenic trioxide (ATO) combined with cytosine arabinoside (ara-c) for the treatment of advanced myelofibrosis and myelofibrosis transformed to acute myeloid leukemia"


Xiaomei Ma, PhD
Yale University School of Medicine
"Epidemiology of Chronic Myeloproliferative Disorders Grant"


Alison Moliterno, MD
Johns Hopkins
"Proteomic Approach to the Diagnosis of Chronic MPD's.

Mingjiang Xu, MD, Ph.D.
University of Illinois, at Chicago
"Exploration of a unique phosphatase as a potential therapeutic target for treatment of PV"

Ron Hoffman, MD
University of Illinois at Chicago
"Continuation of 2003 grant. "

Jose Lopez, MD
Baylor College of Medicine
"Macrophage-derived Prothrombotic Microparticles and Thrombosis in Myeloproliferative Disorders"


Xiao-Feng Yang, MD, PhD
Baylor College of Medicine
"Novel Antigen targets for Immunotherapy in the Myeloproliferative Diseases"

Ruben Mesa, MD
Mayo Clinic, Rochester, NY
"Novel therapies for Myelofibrosis with Myeloid Metaplasia"

Richard D'Andrea, MD
Child Health Research Institute, Australia
"Identification of Growth Factor Receptor Mutations in Polycythemia Vera"

Ron Hoffman, MD
University of Illinois at Chicago
"Organizational grant for International MPD Research Consortium in application for $25 million grant from NCI"

Vahid Afshar-Kharghan, MD
Baylor College of Medicine
"Continuation of 2002 Grant"


Vahid Afshar-Kharghan
MD Baylor College of Medicine
"Genetic factors that influence platelet function in PV and ET, and their effect on the frequency of thrombotic complications."

Dr. Josef Prchal
Baylor College of Medicine
"Continuation of 2001 Grant"

Dr. Josef Prchal
Baylor College of Medicine
"Continuation of 2000 Grant"


Dr. Josef Prchal
Baylor College of Medicine
"Locate and identify the gene or genes whose defects are responsible for ET."

Dr. Josef Prchal
Baylor College of Medicine
"Continuation of 2000 Grant"


Dr. Josef Prchal
Baylor College of Medicine
"Locate and identify the gene or genes that lead to the development of the Polycythemia Vera phenotype."


Subscribe to updates to learn more about available MPN treatments.


Polycythemia Vera (PV)

Meet Kenny

Take the steps you need to help change your prognosis.



Get free, timely information on living with an MPN.